SK&F 106760 | | Glycoprotein IIb/IIIa antagonist

MedKoo Cat#: 598088 | Name: SK&F 106760

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SK&F 106760 is a glycoprotein IIb/IIIa antagonist.

Chemical Structure

SK&F 106760

CAS#126053-71-2

Theoretical Analysis

MedKoo Cat#: 598088

Name: SK&F 106760

CAS#: 126053-71-2

Chemical Formula: C23H39N9O8S2

Exact Mass: 633.2363

Molecular Weight: 633.74

Elemental Analysis: C, 43.59; H, 6.20; N, 19.89; O, 20.20; S, 10.12

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

SK&F 106760; SK&F-106760; SK&F106760; SKF 106760; SKF-106760; SKF106760;

IUPAC/Chemical Name

2-((4R,7S,13R,16R)-16-acetamido-4-carbamoyl-13-(3-guanidinopropyl)-3,3,14-trimethyl-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetraazacycloheptadecan-7-yl)acetic acid

InChi Key

MWLMZCNGBAIZSG-SZOQZIPDSA-N

InChi Code

InChI=1S/C23H39N9O8S2/c1-11(33)29-13-10-41-42-23(2,3)17(18(24)37)31-19(38)12(8-16(35)36)30-15(34)9-28-20(39)14(32(4)21(13)40)6-5-7-27-22(25)26/h12-14,17H,5-10H2,1-4H3,(H2,24,37)(H,28,39)(H,29,33)(H,30,34)(H,31,38)(H,35,36)(H4,25,26,27)/t12-,13-,14+,17+/m0/s1

SMILES Code

O=C(N[C@@H](CC(O)=O)C(N[C@@H](C(C)(C)SSC[C@@H](C(N([C@@H]1CCCNC(N)=N)C)=O)NC(C)=O)C(N)=O)=O)CNC1=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 633.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Willette RN, Sauermelch CF, Rycyna R, Sarkar S, Feuerstein GZ, Nichols AJ, Ohlstein EH. Antithrombotic effects of a platelet fibrinogen receptor antagonist in a canine model of carotid artery thrombosis. Stroke. 1992 May;23(5):703-11. PubMed PMID: 1605806. 2: Nichols AJ, Vasko JA, Valocik RE, Kopaciewicz LJ, Storer BL, Ali FE, Romoff T, Calvo R, Samanen JM. The in vitro pharmacological profile of SK&F 106760, a novel GPIIB/IIIA antagonist. Thromb Res. 1994 Jul 15;75(2):143-56. PubMed PMID: 7974388. 3: Nichols AJ, Vasko JA, Koster PF, Valocik RE, Rhodes GR, Miller-Stein C, Boppana V, Samanen JM. The in vivo pharmacological profile of the novel glycoprotein IIb/IIIa antagonist, SK&F 106760. J Pharmacol Exp Ther. 1994 Aug;270(2):614-21. PubMed PMID: 8071853. 4: Constantinides PP, Scalart JP, Lancaster C, Marcello J, Marks G, Ellens H, Smith PL. Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides. Pharm Res. 1994 Oct;11(10):1385-90. PubMed PMID: 7855039. 5: Samanen J, Wilson G, Smith PL, Lee CP, Bondinell W, Ku T, Rhodes G, Nichols A. Chemical approaches to improve the oral bioavailability of peptidergic molecules. J Pharm Pharmacol. 1996 Feb;48(2):119-35. Review. PubMed PMID: 8935160. 6: Willette RN, Storer BL, Clark RK, Ohlstein EH. Human laminin produces human platelet aggregation in vitro. Life Sci. 1994;55(5):379-88. PubMed PMID: 8035652. 7: Horton MA, Dorey EL, Nesbitt SA, Samanen J, Ali FE, Stadel JM, Nichols A, Greig R, Helfrich MH. Modulation of vitronectin receptor-mediated osteoclast adhesion by Arg-Gly-Asp peptide analogs: a structure-function analysis. J Bone Miner Res. 1993 Feb;8(2):239-47. PubMed PMID: 7680185. 8: Ali FE, Bennett DB, Calvo RR, Elliott JD, Hwang SM, Ku TW, Lago MA, Nichols AJ, Romoff TT, Shah DH, et al. Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregation. J Med Chem. 1994 Mar 18;37(6):769-80. PubMed PMID: 8145226. 9: Samanen J, Ali F, Romoff T, Calvo R, Sorenson E, Vasko J, Storer B, Berry D, Bennett D, Strohsacker M, et al. Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro. J Med Chem. 1991 Oct;34(10):3114-25. PubMed PMID: 1920361.